Nuvation Bio Inc.

Nuvation Bio Inc. (NYSE: NUVB) is a clinical-stage biopharmaceutical company focused on developing novel therapies for patients with cancer, with a pipeline targeting both hematologic malignancies and solid tumors. The company became publicly traded in February 2022 following a business combination with Panacea Acquisition Corp. II, a SPAC that completed its IPO in 2021 under the sponsorship of Panacea Holdings II LLC. Founded by oncologist David Hung, who previously co-founded Medivation, Nuvation Bio filed an 8-K current report with the SEC on April 10, 2024, continuing its standard disclosure obligations as a listed company. For complete filings, pipeline milestones, and deal-level analytics on Nuvation Bio and the broader SPAC universe, sign up for full data access on SpacDesk.